Markets:

Overview

News

Currencies

International

Treasuries

CAMP4 Therapeutics Corporation - Common Stock (NQ:CAMP)

4.550 -0.090 (-1.94%)

Streaming Delayed Price Updated: 2:07 PM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CAMP4 Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.

Via The Motley Fool

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock.

Via The Motley Fool

Topics Regulatory Compliance

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

Via The Motley Fool

Topics Regulatory Compliance

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

Via The Motley Fool

3 Healthcare Companies Insiders Are Buying ↗

October 14, 2025

Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years.

Via MarketBeat

Topics Initial Public Offering

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 10, 2025

Via Benzinga

Wednesday's after hours session: top gainers and losers ↗

September 10, 2025

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 10, 2025

Via Benzinga

Camp4 Reports Q2 Revenue Beats Estimates ↗

August 14, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 28, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 11, 2025

Via Benzinga

This Sandisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

May 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 06, 2025

Via Benzinga

Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket ↗

May 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 02, 2025

Via Benzinga

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 ↗

April 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 17, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 06, 2024

Via Benzinga

Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

December 06, 2024

Via Benzinga

CAMP4 Analyst Highlights Rare Disease Platform Potential ↗

November 05, 2024

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036.

Via Benzinga

Topics Initial Public Offering

Another Trio Of Biotech IPOs Made Friday Debut ↗

October 13, 2024

The Partners Group-backed KinderCare sold 24 million shares for $24 each this past Tuesday. Meanwhile, a new trio of biotech companies' shares came to market on Friday, as Upstream Bio, CeriBell, and...

Via Talk Markets

Preview: Camp4 Therapeutics Corporation Set To IPO Tomorrow ↗

October 10, 2024

Via Benzinga

Topics Initial Public Offering

12 Information Technology Stocks Moving In Tuesday's After-Market Session ↗

June 11, 2024

Via Benzinga

Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 11, 2024

Via Benzinga

12 Information Technology Stocks Moving In Tuesday's Intraday Session ↗

June 11, 2024

Via Benzinga

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session ↗

June 11, 2024

Via Benzinga

12 Information Technology Stocks Moving In Friday's Pre-Market Session ↗

June 07, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.